BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for VistaGen Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:28 pm Purchase | 2024-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | BIOTECHNOLOGY VALUE FUND L P | 3,084,324 9.970% | 307,079 (+11.06%) | Filing |
| 2023-10-16 4:34 pm Purchase | 2023-10-04 | 13G | VistaGen Therapeutics, Inc. VTGN | BIOTECHNOLOGY VALUE FUND L P | 2,777,245 9.990% | 2,777,245 (New Position) | Filing |